摘要
目的报道1例脐尿管癌患者扩大性膀胱部分切除术后,采用紫杉醇脂质体与卡铂(TC)方案化疗序贯替雷利珠治疗,分析该治疗模式的有效性和安全性,为临床治疗提供参考。方法分析1例61岁男性脐尿管癌患者的临床资料、治疗方案应用情况和随访结果,并结合国内外文献进行分析探讨。结果术前腹部增强CT提示脐尿管癌可能,膀胱镜观察膀胱顶部占位,遂行扩大性膀胱部分切除术,术后病理示脐尿管腺癌、切缘阴性。术后予以紫杉醇脂质体与卡铂治疗4周期,序贯予以替雷利珠单抗治疗4周期,随访16个月肿瘤无复发及远处转移。结论脐尿管癌临床发病率低,早期诊断困难,以手术治疗为主结合化疗序贯予以免疫治疗的方法可以达到良好的治疗效果。
Objective The efficacy and safety of the treatment model were analyzed provide a reference for clinical treatment in a patient with urachal carcinoma who underwent extended partial cystectomy and was treated with Paclitaxel liposome-carboplatin(TC)regimen sequential Tislelizumab.Methods The clinical data,application of treatment plan and follow-up results of a 61-year-old male patient with urachal carcinoma were analyzed and discussed in combination with domestic and foreign literature.Results Preoperative enhanced CT of the abdomen revealed the possibility of urachal carcinoma.Cystoscopy indicated the top of the bladder and performed extended partial cystectomy.Postoperative pathology showed urachal adenocarcinoma and negative margins.After the treatment of 4-cycle chemotherapy with TC regimen and sequential tislelizumab treatment,the 16-month follow-up results didn’t exhibit the recurrence and distant metastasis of this tumor.Conclusion Surgical treatment is the first line of treatment for primary urachal carcinoma.For achieving the better therapeutic effects,the TC regimens sequential Tislelizumab should be considered preferentially.
作者
陈杰勋
陈冬明
王恺
王冬
许贤林
CHEN Jie-xun;CHEN Dong-ming;WANG Kai;WANG Dong;XU Xian-lin(Department of Urological Surgical,Sir Run Run Hospital,Nanjing Medical University,Nanjing 21000,Jiangsu Province,China)
出处
《罕少疾病杂志》
2022年第5期10-12,16,共4页
Journal of Rare and Uncommon Diseases
作者简介
第一作者:陈杰勋,男,主治医师,主要研究方向:泌尿系肿瘤。E-mail:cjx128619@yeah.net;通讯作者:许贤林,男,主任医师,主要研究方向:肾移植及泌尿系肿瘤。E-mail:xianlinxu@njmu.edu.cn。
